Ovarian suppression in breast cancer management
DOI:
https://doi.org/10.22141/oncology.2.1.2019.165447Keywords:
breast cancer, endocrine therapy, ovarian suppression, reviewAbstract
The review summarizes current data about the role of ovarian suppression/ablation in endocrine therapy for breast cancer. Information of the indications and methods of ovarian suppression is given; the characteristics of modern drugs used for this purpose — gonadotropin-releasing hormone agonist — are presented, including their advantages and possible side effects. The review contains a description of the evolution of views on the indications for ovarian suppression based on the data from the most authoritative and reliable clinical trials. The latest data from leading international guidelines on the scope of ovarian suppression/ablation in the palliative, adjuvant and neoadjuvant modes are discussed.References
4rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4) / F. Cardoso, E. Senkus, A. Costa // Annals of Oncology. — 2018. — 29. — 1634-1658. doi: 10.1093/annonc/mdy192.
ASCO Endorsement of the CCO Practice Guideline on Adjuvant Ovarian Ablation in the Treatment of Premenopausal Women with Early Stage Invasive Breast Cancer // Journal of Clinical Oncology. — 2011. — Vol. 29, Issue 29. — 3939-3942.
Charehbili A., Fontein D., Kroep J. et al. Neoadjuvant hormonal therapy for endocrine sensitive breast cancer: A systematic review // Cancer Treatment Reviews Volume. — 2014. — 40, 1. — 86-92.
Crump M., Sawka C.A., DeBoer G. et al. An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cance // Breast Cancer Res. Treat. — 1997. — 44. — 201-210.
EBCТCG. Ovarian ablation in early breast cancer: overview of the randomised trials // Lancet. — 1996. — 348. — 1189-1196.
Eisen A., Messersmith H., Franek J., Trudeau M. Breast Cancer Disease Site Group. Adjuvant ovarian ablation in the treatment of premenopausal women with early stage invasive breast cancer // Cancer Care Ontario. — 2010 Jul 6. Program in Evidence-based Care Evidence-based Series.
Elective and risk-reducing salpingo-oophorectomy / American College of Obstetricians and Gynecologists practice bulletin // Obstet. Gynecol. — 2008. — 111 (1). — 231-41.
Emons G., Grundker C., Gunthert A.R. et al. GnRH antagonists in the treatment of gynecological and breast cancers Endocrine-Related // Cancer. — 2003. — 10291-299.
Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline / Rugo H.S., Rumble R.B., Macrae E. et al. // J. Clin. Oncol. — 2016. — 34 (25). — 3069-103. doi: 10.1200/JCO.2016.67.1487.
Fleming G., Francis P.A., Láng I. et al. Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Update of the SOFT trial // SABCS Publication Number: GS4-03. https://www.sabcs.org/Portals/SABCS2016/Documents/SABCS-2017-Abstracts.pdf
Gnant M., Harbeck N., Thomssen C. A Brief Summary of the Consensus Discussion about Escalation and De-Escalation of Primary Breast // Cancer Treatment Breast Care. — 2017. — 12. — 102-107. doi: 10.1159/000475698.
Jackischa C., Harbeckb N., Huoberc J. et al. 14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus — Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts Breast Care // 2015. — 10. — 211-219. doi: 10.1159/000433590.
Klijn J.G.M., Blamey R.W., Boccardo F. et al. Сombined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials // J. Clin. Oncol. — 2001. — 19 (2). — 343-53.
Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up clinical practice guidelines / F. Cardoso, N. Harbeck, L. Fallowfield, S. Kyriakides, E. Senkus // Annals of Oncology 23 (Suppl. 7). — 2012. —11-19. doi: 10.1093/annonc/mds232.
National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 2.2018. https://www.nccn.org/store/login/login.aspx?Return URL = https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf
Pagani O., Regan M.M., Fleming G.F. et al. Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor positive (HR+) early breast cancer (BC): Update of the combined TEXT and SOFT trials // 2017 SABCS Publication Number: GS4-02. https://www.sabcs.org/Portals/SABCS2016/Documents/SABCS-2017-Abstracts.pdf
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up / Senkus E., Kyriakides S., Ohno S. et al. ESMO Guidelines Working Group // Ann. Oncol. — 2015. — 26 (suppl. 5). — 8-30. doi: 10.1093/annonc/mdv29.
Pritchard K.I. Current and future directions in medical therapy for breast carcinoma: endocrine treatment // Cancer. — 2000. — 88. — 3065-3072.
Regan M.M., Pagani O., Francis P.A. et al. Absolute improvements in freedom from distant recurrence with adjuvant endocrine therapies for premenopausal women with hormone receptor-positive (HR+) HER2-negative breast cancer (BC): Results from TEXT and SOFT. ASCO Abstract #503 https://meetinglibrary.asco.org/record/160255/abstract
Robertson J.F., Blamey R.W. The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women // Eur. J. Cancer. — 2003. — 39. — 861-869.
Woo Chul Noh, Jong Won Lee, Seok Jin Nam et al. The role of the addition of ovarian suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or regain menstruation after chemotherapy (ASTRRA): Study protocol for a randomized controlled trial and progress // J. Clin. Oncol. — 2018. — 36 (suppl; abstr 502).
Щепотин И.Б., Зотов А.С., Лебедева О.И. Рак грудной железы и репродуктивная функция женщины: рак грудной железы у беременных и вопросы сохранения фертильности после лечения // Клиническая онкология. — 2012. — № 5 (1). — С. 59-63.
Щепотин И.Б., Зотов А.С., Любота Р.В. и др. Роль подавления функции яичников в комплексной терапии больных раком молочной железы в пременопаузе (обзор литературы) // Вопр. онкологии. — 2013. — Т. 59, № 3. — С. 397-404.
Щепотін І.Б., Зотов О.С., Любота Р.В. та ін. Індукована хіміотерапією аменорея у хворих на рак молочної залози: основні механізми та діагностичні критерії порушення функції яєчників (огляд літератури) // Клін. ендокр. та ендокр. хірургія. — 2013. — № 2 (43). — С. 3-9.
Щепотін І.Б., Зотов О.С., Любота Р.В., Любота І.І. Значення супресії функції яєчників у лікуванні хворих на рак молочної залози в пременопаузі (огляд літератури) // Клін. ендокр. та ендокр. хірургія. — 2013. — № 1 (42). — С. 26-33.
Downloads
Issue
Section
License
Copyright (c) 2019 Practical oncology

This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
- The rights to the article are deemed transferred by the authors to the edition (the publisher) since the moment of the publication of the article in the printed or electronic version of journal.